This is a Phase I study of the agent, lenalidomide (CC-5013) in pediatric patients with CNS tumors. The primary objective is to determine the maximum tolerated dose of this agent and a recommended Phase II dose. Patients on this study are less than 22 years of age and have a recurrent, progressive or refractory CNS tumor. Patients are treated with lenalidomide given orally for 21 days of a 28 day cycle. Dose escalations were based on absence of toxicities for each dose level in course 1. The study has accrued quickly and has reached its accrual goals. The study is currently under analysis and results will be presented at the Society of Neuro-Oncology in November 2008.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010585-05
Application #
7733095
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2008
Total Cost
$30,829
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code